Advances and challenges in the treatment of myelodysplastic syndromes
Myelodysplastic syndromes Myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the bone
Myelodysplastic Syndromes (MDS)
Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes
Purpose: Tumor Protein 53 (p53) expressed from gene TP53 is a seminal tumor suppressor.
Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review
Allogeneic hematopoietic stem-cell transplantation (HCT) remains the only potentially curative therapy for patients with myelodysplastic neoplasms (MDS) and myelofibrosis (MF) and is the standard care for eligible patients with higher-risk disease. Despite significant advancements, both diseases pose unique challenges due to their clinical and molecular heterogeneity, necessitating personalized approaches to patient selection, timing, and transplant management. For MDS, genomic profiling has revolutionized prognostic frameworks such as IPSS-M, enabling tailored therapeutic decisions.
New Approvals in Low- and Intermediate-Risk Myelodysplastic Syndromes
Recent advances in defining low- and intermediate-risk myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PL
Germline and somatic genetic landscape of pediatric myelodysplastic syndromes
Pediatric myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders wher
Marching Through MDS: Veterans and the Battle Against Myeloid Neoplasms
Topic(s)
Myelodysplastic Syndromes (MDS)
Presenter(s)
Christin DeStefano, MD, FACP
Drew A. Helmer, MD, MS
In this webinar, Drs. Christin Destefano and Drew Helmar discuss the link between military toxic exposure and hematologic malignancies.
Jesus Gonzalez Lugo, MD
Institution
The University of Kansas
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Praneeth Baratam, MBBS
Institution
Medical University of South Carolina
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)